HeyJaredBiotech CEO Sisterhood
Members of the Biotech CEO Sisterhood regularly interview women leaders in biotech about news, science, management topics and more. Tune in to hear from top leaders in biotech about topics that matter to the industry.
- Indexed episodes, last 90 days
- 4
- Latest publication
- Sep 3, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 23, 2026
Latest episodes
Former BIO CEO Rachel King describes her career and shares advice on what makes a successful biotech CEO (opens the original)
Read excerpt
Interviewed by Sisterhood Editorial Board Member Erika Smith, Rachel King reflects on her time at NEA and 18 years as the Co-Founder & CEO at GlycoMimetics, as well as stepping into the role of BIO's CEO on an interim basis. She offers leadership advice, and describes the ways she still says active in biotech today.
Katherine Stueland describes joining GeneDx as a first time CEO during a turbulent time and reshaping it into a leader in genetic testing for rare disease diagnosis (opens the original)
Read excerpt
She describes how the mission of getting the company on stable ground through financial discipline and a sharper focus on strategy has enabled it to thrive and deliver on its mission for patients. Plus, her advice to others having gone through it as a first time CEO.
Amy Burroughs discusses the success of Terns Pharma and developing TERN-701 for CML, being acquired by Merck for $6.7 billion, and leadership learnings throughout her career (opens the original)
Read excerpt
Interviewed by Sisterhood editorial board member Erika Smith, Amy Burroughs discusses joining Terns when it was not obvious and at a time when the company was going through a sad moment, and how the momentum started to turn as data for TERN-701 started becoming apparent. She describes her career, which included stops at large and small companies, and on the investing side at 5AM Ventures, and provides leadership lessons along the way.
Fresh off of a successful IPO, Avalyn Pharma CEO Lyn Baranowski describes the company's inhaled medicines platform, and shares her secrets to success as a leader (opens the original)
Read excerpt
Interviewed by Sisterhood editorial board member Erika Smith, Lyn Baranowski highlights the company's $345 million IPO, which enables it to further develop its inhaled medicines. She describes why they believe this delivery method provides a more direct and efficient way to treat fibrotic lung conditions like IPF.
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.